Literature DB >> 11233911

Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model.

X Préville1, M Flacher, B LeMauff, S Beauchard, P Davelu, J Tiollier, J P Revillard.   

Abstract

BACKGROUND: The mechanisms of action of polyclonal antithymocyte globulins (ATGs) are still poorly understood and the selection of doses used in different clinical applications (prevention or treatment of acute rejection in organ allografts, treatment of graft-versus-host disease, or conditioning for allogeneic stem cell transplantation) remains empirical. Low T-cell counts are usually achieved in peripheral blood during ATG treatment but the extent of T-cell depletion in lymphoid tissues is unknown.
METHODS: Experiments were conducted in cynomolgus monkeys using Thymoglobuline at low (1 mg/kg), high (5 mg/kg), and very high (20 mg/kg) doses.
RESULTS: ATG treatment induced a dose-dependent lymphocytopenia in the blood and a dose-dependent T-cell depletion in spleen and lymph nodes but not in the thymus, indicating a limited access of ATG to this organ. T-cell apoptosis in peripheral lymphoid tissues was the main mechanism of depletion. Remaining T cells in peripheral lymphoid organs were coated by antibodies and had down-modulated surface expression of CD2, CD3, CD4, and CD8 molecules, whereas their responsiveness in mixed leukocyte reaction was impaired. The survival of MHC-mismatched skin and heart allografts was prolonged in a dose-dependent fashion, despite the occurrence of a strong anti-ATG antibody response resulting in the rapid clearance of circulating ATGs.
CONCLUSION: The results indicate that T-cell depletion is achieved rapidly and primarily in peripheral lymphoid tissues at high ATG dosage. Short ATG treatments could therefore be clinically evaluated when major peripheral T-cell depletion is required.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11233911     DOI: 10.1097/00007890-200102150-00021

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  60 in total

1.  Tolerogenic immunosuppression for organ transplantation.

Authors:  Thomas E Starzl; Noriko Murase; Kareem Abu-Elmagd; Edward A Gray; Ron Shapiro; Bijan Eghtesad; Robert J Corry; Mark L Jordan; Paulo Fontes; Tim Gayowski; Geoffrey Bond; Velma P Scantlebury; Santosh Potdar; Parmjeet Randhawa; Tong Wu; Adriana Zeevi; Michael A Nalesnik; Jennifer Woodward; Amadeo Marcos; Massimo Trucco; Anthony J Demetris; John J Fung
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

Review 2.  Current landscape for T-cell targeting in autoimmunity and transplantation.

Authors:  Daniel R Getts; Sushma Shankar; Emily M L Chastain; Aaron Martin; Meghann Teague Getts; Kathryn Wood; Stephen D Miller
Journal:  Immunotherapy       Date:  2011-07       Impact factor: 4.196

3.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.

Authors:  Xingmin Feng; Sachiko Kajigaya; Elena E Solomou; Keyvan Keyvanfar; Xiuli Xu; Nalini Raghavachari; Peter J Munson; Thomas M Herndon; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

Review 4.  Lymphodepletional strategies in transplantation.

Authors:  Eugenia Page; Jean Kwun; Byoungchol Oh; Stuart Knechtle
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

5.  Impact of irradiation and immunosuppressive agents on immune system homeostasis in rhesus macaques.

Authors:  C Meyer; J Walker; J Dewane; F Engelmann; W Laub; S Pillai; Charles R Thomas; I Messaoudi
Journal:  Clin Exp Immunol       Date:  2015-06-29       Impact factor: 4.330

Review 6.  The effects of immunosuppression on regulatory CD4(+)CD25(+) T cells: impact on immunosuppression selection in transplantation.

Authors:  Aqeel Javeed; Yong Zhao
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 7.  Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Authors:  Frank Waldron-Lynch; Kevan C Herold
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

8.  Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.

Authors:  Kenneth R McCurry; Aldo Iacono; Adrianna Zeevi; Samuel Yousem; Alin Girnita; Shahid Husain; Diana Zaldonis; Bruce Johnson; Brack G Hattler; Thomas E Starzl
Journal:  J Thorac Cardiovasc Surg       Date:  2005-08       Impact factor: 5.209

Review 9.  Memory T-cell-specific therapeutics in organ transplantation.

Authors:  Andrew J Page; Mandy L Ford; Allan D Kirk
Journal:  Curr Opin Organ Transplant       Date:  2009-12       Impact factor: 2.640

10.  Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity.

Authors:  Diana Stauch; Annelie Dernier; Elizabeth Sarmiento Marchese; Kristina Kunert; Hans-Dieter Volk; Johann Pratschke; Katja Kotsch
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.